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Abstract
Background: This study was conducted to evaluate the performance of a whole-blood interferon-gamma release
assay in inpatients who were admitted to the emergency department (ED) with pulmonary infiltrates who required
a differential diagnosis with pulmonary tuberculosis (TB).
Methods: The patients with pulmonary infiltrates who received a QuantiFERON (QFT) test in the ED were included
as an inpatient group and were divided into TB and non-TB group based on the final diagnosis. Patients with
pulmonary TB who were tested in the outpatient department served as a control group.
Results: In total, 377 QFT tests were analyzed. Of the 284 inpatient QFT tests, 29.6% had an indeterminate result
(35.2% in the 196 patients with non-TB and 17.0% in the 88 patients with TB). In contrast, only 1.1% of the 93
outpatients with TB returned an indeterminate result (p < 0.001). The indeterminate QFT results in the inpatient
group were independently associated with lymphocytopenia, hypoalbuminemia, and high C-reactive protein levels.
Non-positive QFT results in inpatients with TB were associated with lymphocytopenia and hypoalbuminemia, while
non-positive QFT results in outpatients with TB were associated with high erythrocyte sedimentation rates and
radiographically more severe diseases.
Conclusions: QFT tests in ED-based inpatients with pulmonary infiltrate return indeterminate results relatively
frequently. In addition, inpatients and outpatients with pulmonary TB may differ in terms of the risk factors on non-
positive QFT results.
Background
The whole-blood interferon-gamma release assay
(IGRA) is a new type of rapid, immune-based blood test
that has significantly aided the diagnosis of tuberculosis
(TB) infection [1-3]. However, since the test measures
an immunological response, its performance is likely to
be affected by differences in mycobacterial activity and
factors that suppress the host’s immune system, in parti-
cular cellular immunity. Indeed, we often encounter
patients whose IGRA has returned an indeterminate
result. The high rate of indeterminate results has led to
concern about using new IGRAs, especially when
dealing with patients whose cellular immunity is likely
to be impaired [4,5]. However, to date, few studies have
sought to identify the factors that are associated with
the indeterminate results of IGRA test [6-10].
To address these issues, this study was conducted to
assess whether the performance of IGRA test would be
affected by the manner of presentation to the hospital.
The emergency departments (ED) of Korean hospital
often receive patients with pulmonary infiltrates asso-
ciated with acute derangement. Since Korea is an area
with an intermediate burden of active tuberculosis [11], it
is frequently challenging for clinicians to distinguish
between TB and non-TB. In such clinical situation, IGRA
test for the diagnosis of TB infection may be helpful as a
supplemental tool for the diagnostic exclusion of active
TB [12]. Thus, we investigated the performance of IGRA
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any medium, provided the original work is properly cited.test in these ED inpatients and compared it with its per-
formance in outpatients with pulmonary TB. In addition,
we sought to identify the factors that influence the per-
formance of IGRA test in both inpatients and outpatients
with active pulmonary TB.
Methods
Study population and design
At the Kyungpook National University Hospital between
March 1, 2009 and June 30, 2010, patients older than 18
years who presented at the ED with acute respiratory
symptoms, and whose chest radiographs exhibited pul-
monary infiltrates were hospitalized and routinely tested
with one of two QuantiFERON tests (QFT), namely,
QuantiFERON
®- T BG o l d( Q F T - G )a n dQ u a n t i -
FERON
®-TB Gold In-Tube (QFT-GIT) (both are from
Cellestis Ltd., Carnegie, Australia). The patients who
received a QFT test at the ED were prospectively
enrolled as an inpatient group of this study. Patients
with HIV infection, known lung cancer, or overt lung
mass suggesting lung cancer were excluded. Moreover,
the patients who were diagnosed with pulmonary TB
and received a QFT test before the initiation of anti-TB
treatment at the outpatient department (OPD) during
the same period were recruited as a control group. The
patients in the control group were not hospitalized until
the end of treatment except if problems arose, such as
non-respiratory disease or drug intolerance. The clinical,
laboratory, and radiographic data and the results of
QFT test were collected in both groups.
The diagnosis of TB was definitely confirmed for all
TB patients by culturing Mycobacterium tuberculosis in
their sputum or bronchial aspirate. Diseases other than
TB were finally diagnosed by pathology, culture results,
and follow-up chest radiographs. In patients with pul-
monary TB, the radiographic extent of the lesion was
simply classified as mild, moderate, and advanced
groups. Thus, lesions extending to within one-third of
the unilateral lung field, within the unilateral lung field
beyond one-third of the field, and beyond the unilateral
lung field were classified as mild, moderate, and
advanced, respectively [10]. The study was approved by
the institutional research board of Kyungpook National
University Hospital, and informed consent was waived.
QFT test (QFT-G/QFT-GIT)
The QFT-G test was replaced by the QFT-GIT test during
the study period. In total, 128 and 249 patients were tested
with QFT-G and QFT-GIT, respectively. The tests were
performed according to the recommendations of the manu-
facturers [13] by trained technicians. In brief, the tests con-
sisted of a negative control, a positive control, and two
sample wells (whole-blood stimulated with either early
secretary antigenic target 6 (ESAT-6) or culture filtrate
protein (CFP-10)) for the QFT-G test or three heparinized
t u b e s( at e s tt u b ec o n t a i n i n gt h eE S A T - 6 ,C F P - 1 0 ,a n d
TB7.7 peptide cocktail, a positive control, a negative con-
trol) for the QFT-GIT test. Whole-blood specimens con-
tained in wells or tubes were incubated for 16-20 h at 37°C
in a carbon dioxide incubator. The IFN-g titer of the nega-
tive well is considered to be the background value and is
subtracted from the values of the mitogen control and the
antigen-stimulated wells. The samples are considered to be
positive if their TB antigen-stimulated IFN-g titers are ≥0.35
IU/ml, regardless of the positive control result. The samples
are considered to be negative if their TB antigen-stimulated
IFN-g titers are <0.35 IU/ml and their positive control titers
are ≥0.5 IU/ml. The test result is considered to be indeter-
minate if TB antigen- and mitogen-stimulated IFN-g titers
are <0.35 IU/ml and <0.5 IU/ml, respectively [13].
Statistical analysis
The c
2 or the Fisher exact test, if there were ≤ 5 obser-
vations, was used to compare the findings between the
two groups. The T-test was performed to determine the
statistical significance of differences between means of
some variables. The effects of age, sex, and immune sta-
tus on the probability of obtaining an indeterminate
QFT result were analyzed by logistic regression analysis.
P values < 0.05 were considered significant. Statistical
analyses were performed by using statistical software
(SPSS for Windows, version 17.0).
Results
Baseline characteristics of the study population
Overall, 284 inpatients and 93 outpatients were recruited.
Baseline characteristics of all 377 patients are shown in
Table 1. Among inpatients, 88 patients (31.0%) were
diagnosed with pulmonary TB. The remaining inpatients
were finally diagnosed with pneumonia (n = 178), orga-
nizing pneumonia (n = 7), nontuberculous mycobacterial
lung disease (n = 5), aspergillosis (n = 4), and lung cancer
(n = 2), respectively. Twenty-six patients had risk factors
for immunosuppression, such as renal failure (n = 11),
malignancies that were not receiving anti-cancer treat-
ments at the time of testing with QFT (n = 7), and
immunosuppressive therapies including cancer che-
motherapy (n = 9) and systemic steroids (n = 2).
Performance of QFT test in inpatients with pulmonary
infiltrates and outpatients with TB
Table 2 summarizes the QFT results of the 377 patients
divided according to whether they were inpatients or
outpatients; the inpatients were also further divided
according to whether non-TB or TB was diagnosed. Of
the 284 inpatients, 84 (29.6%) had an indeterminate
QFT result. All of them were attributed to the absence
of sufficient response to mitogen control. Of the
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indeterminate QFT results, respectively. This difference
was statistically significant (p = 0.002). Of the 93 outpa-
tients, all of whom had pulmonary TB, there was only
one indeterminate QFT result (1.1%). The inpatients
with pulmonary TB were significantly more likely to
have indeterminate QFT results than the outpatients
(17.0% vs. 1.1%, respectively, p < 0.001). In addition, the
sensitivity of QFT test for the diagnosis of active TB
was significantly lower for inpatients than outpatients
(58.0% vs. 82.8%, p < 0.001). The negative predictive
value of QFT test was 82.1% in the inpatient group.
Univariate and multivariate analysis of factors associated
with indeterminate QFT results in inpatients with
pulmonary infiltrates
The clinical and laboratory findings of the 84 inpatients
whose QFT results were indeterminate were compared
to those of the remaining 200 inpatients, whose QFT
results were determinate. Univariate analysis revealed
that patients with indeterminate QFT results were sig-
nificantly older, more likely to have lymphocytopenia
(lymphocyte count less than 1000 cells/μL), and had
lower lymphocyte counts, lower albumin concentrations,
higher C-reactive protein (CRP) levels than those with
determinate results (Table 3). Gender, body mass index,
prior TB treatment history, and underlying conditions
including immunosuppressive therapies did not associate
significantly with the occurrence of indeterminate
results in inpatients. Multivariate analysis then revealed
that patients with indeterminate QFT results had signifi-
cantly lower albumin concentrations and higher CRP
levels than those with determinate results. They were
also significantly more likely to have lymphocytopenia.
Comparison of inpatients and outpatients with
pulmonary TB with regard to the factors associated with
non-positive QFT results
Since the inpatients and outpatients with pulmonary TB
differed significantly with regard to the sensitivity of the
Table 1 Baseline characteristics of the study population
Characteristics Inpatients Outpatients
Total (n = 284 ) * Non- TB (n = 196) TB (n = 88) TB (n = 93)
Age, yr 63 ± 16.5 65 ± 14.5 59 ± 19.8 52 ± 19.5
Male 206 (72.5) 150 (76.5) 56 (63.6) 50 (53.8)
Body mass index 21.4 ± 3.50 21.7 ± 3.42 20.8 ± 3.61 21.7 ± 3.08
Prior TB history 57 (20.1) 39 (19.9) 18 (20.5) 16 (17.2)
Underlying conditions
Renal failure 11 (3.9) 9 (4.6) 2 (2.3) 0 (0)
Malignancy† 4 (1.4) 2 (1.0) 2 (2.3) 3 (3.2)
Immunosuppressive therapy‡ 11 (3.9) 7 (3.6) 4 (4.5) 0 (0)
Data are shown as mean ± SD or No. (%). TB, tuberculosis.
* Patients with pneumonia (n = 178), organizing pneumonia (n = 7), nontuberculous mycobacterial lung disease (n = 5), aspergillosis (n = 4), and lung cancer (n
= 2).
† Patients with a diagnosis of cancer who were not receiving anti-cancer treatment, including lung cancer (n = 2), hypopharyngeal cancer (n = 1), and gastric
cancer (n = 1) for inpatients; hepatocellular carcinoma (n = 1), glottic cancer (n = 1), and gastric cancer (n = 1) for outpatients.
‡ Patients receiving cancer chemotherapy (n = 9 ) or systemic steroids (>10 mg/day of prednisone for ≥ 1 month) (n = 2).
Table 2 Performance of QuantiFERON test in inpatients with pulmonary infiltrates and outpatients with pulmonary
tuberculosis
QuantiFERON† Inpatients p value Outpatients p value
Total
(n = 284)
* Non-TB
(n = 196)
TB
(n = 88)
TB
(n = 93)
Indeterminate 84 (29.6) 69 (35.2) 15 (17.0) 0.002
a 1 (1.1) <0.001
b
Determinate 200 (70.4) 127 (64.8) 73 (83.0) 92 (98.9) <0.001
c
Positive 77 (27.1) 26 (13.3) 51 (58.0) 77 (82.8)
Negative 123 (43.3) 101 (51.5) 22 (25.0) 15 (16.1)
Data are shown as mean ± SD or No. (%). TB, tuberculosis.
† QuantiFERON test was performed by using QuantiFERON
®- TB Gold or QuantiFERON
®-TB Gold In-Tube.
* Patients with pneumonia (n = 178), organizing pneumonia (n = 7), nontuberculous mycobacterial lung disease (n = 5), aspergillosis (n = 4), and lung cancer (n
= 2).
a Comparison of proportion of indeterminate vs. determinate results between in patients with non-TB and TB.
b Comparison of proportion of indeterminate vs. determinate results between inpatients and out patients with TB.
c Comparison of positive QuantiFERON test results between inpatients and outpatients with TB.
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ciated with non-positive QFT results in the two groups.
Table 4 shows the laboratory and radiographic findings
of both the inpatients with TB and the outpatients after
they had been divided according to whether their QFT
result was non-positive. Baseline characteristics were not
significantly different between patients with positive and
non-positive QFT results in both subgroups (data not
shown). The inpatients with non-positive QFT results
had significantly lower mean lymphocyte counts, lower
mean albumin concentrations, and a higher rate of lym-
phocytopenia than those with positive QFT results. In
contrast, the outpatients with non-positive QFT results
had significantly higher mean erythrocyte sedimentation
rates (ESR) and more severe disease (as observed by
radiography) than the outpatients with positive QFT
results. Thus, the inpatients differed from the outpati-
ents in terms of the clinically presented factors that
were associated with a non-positive QFT result.
Discussion
The main findings of this study were: 1) Inpatients
admitted to the ED with either pulmonary TB or non-
TB diseases were significantly more likely to have inde-
terminate QFT results than outpatients with pulmonary
TB; 2) The sensitivity of QFT test for the diagnosis of
pulmonary TB showed significant difference between
inpatients (58.0%) and outpatients (82.8%); 3) Indepen-
dent factors that were associated with indeterminate
QFT results in inpatients were lymphocytopenia, lower
Table 3 Univariate and multivariate analysis of factors associated with indeterminate QuantiFERON results in
inpatients with pulmonary infiltrates
Covariate Determinate
(n = 200)
indeterminate
(n = 84)
Univariate Multivariate
Odds ratio 95% confidence interval Odds ratio 95% confidence interval
Age, yr 62 ± 17.1 67 ± 14.5 1.018 1.001-1.035
Lymphocytes cells/μL 1170 ± 935 764 ± 451 0.999 0.998-0.999
Lymphocytopenia*
Absence 99 (49.5) 19 (22.6) 1.0 1.0
Presence 101 (50.5) 65 (77.4) 3.353 1.875-5.998 2.688 1.424-5.075
Albumin, g/dL 3.4 ± 0.60 3.0 ± 0.54 0.307 0.190-0.495 0.412 0.245-0.694
ESR, mm/hr 58.3 ± 35.88 67.2 ± 32.52 1.007 1.000-1.015
CRP, mg/dL 9.2 ± 8.43 15.7 ± 9.65 1.078 1.046-1.110 1.060 1.027-1.094
Data are shown as mean ± SD or No. (%).
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
QuantiFERON test was performed by using QuantiFERON
®- TB Gold or QuantiFERON
®- TB Gold In-Tube.
* Lymphocytopenia; < 1,000 cells/μL.
Table 4 Comparison of inpatients and outpatients with pulmonary tuberculosis with regard to the factors associated
with non-positive QuantiFERON results
Covariates Inpatients P value Outpatients P value
Positive QFT
(n = 51)
Non-positive QFT
(n = 37)
Positive QFT
(n = 77)
Non-positive QFT
(n 16)
Laboratory findings
WBC, cells/μL 8566 ± 3438 10604 ± 5464 0.050 7723 ± 2372 7526 ± 2212 0.761
Lymphocytes, cells/μL 1203 ± 509 885 ± 440 0.003 1 787 ± 642 1508 ± 504 0.105
Lymphocytopenia* 20 (39.2) 24 (64.9) 0.018 7 (9.3) 1 (7.7) 1.0
Albumin, g/dL 3.6 ±0.64 3.1 ± 0.59 0.003 4.4 ± 0.40 4.1 ± 0.56 0.051
ESR, mm/hr 60.5 ± 35.15 62. 5 ± 35.97 0.806 33.9 ± 27.1 58.1 ± 33.4 0.004
CRP, mg/dL 6.5 ± 6.21 8.3 ± 6.83 0.230 2.1 ± 2.92 0.44 ± 0.30 0.452
Radiographic extent of disease
Mild 19 (37.3 ) 13 (35.1 ) 0.589 55 (71.4 ) 6 (37.5) 0.020
Moderate 19 (37.3) 11 (29.7 ) 21 (27.3) 10 (62.5)
Advanced 13 (25.5) 13 (35.1) 1 (1.3) 0
Data are shown as mean ± SD or No. (%).
WBC, white blood cells; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; QFT = QuantiFERON (performed by QuantiFERON
®-TB Gold or
QuantiFERON
®-TB Gold In-Tube).
* Lymphocytopenia; < 1,000 cells/μL.
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inpatients with TB differed from the outpatients in
terms of the risk factors that were associated with non-
positive QFT results.
Previous large studies have demonstrated that the
QFT, when used routinely in hospitals to diagnose TB
infection, often yields indeterminate results [6,7,9,10].
However, these studies only analyzed cohorts with a
high proportion of immunosuppressed individuals [6,7],
children [9], or preselected patients with suspected TB
and latent TB infection [10]. In addition, the proportion
of patients with active TB in these studies was small.
Moreover, these studies did not discriminate between
inpatients and outpatients. Therefore, the results of
these studies may not adequately reflect the perfor-
mance of the QFT in patients who present at an ED
with pulmonary infiltrates. Our study demonstrates the
performance of the QFT in these inpatients. Our results
suggest that the performance of the QFT in an ED can
vary depending on the disease that is involved and may
be significantly worse than its performance in an OPD
setting. This is the first report of the performance of the
Q F Tw h e ni ti sa p p l i e dr o u t i n e l yi na nE Dt od i f f e r e n -
tially diagnose patients who present with acute respira-
tory symptoms and pulmonary infiltrates.
The QFT sensitivity of all of the TB patients, includ-
ing inpatients and outpatients, was 70.7%, which is
within the range of QFT sensitivities of prior reports,
including those obtained by meta-analysis [14]. Among
prior reports, Mazurek et al. [15] reported QFT-G sensi-
tivity of 69.6% in patients with culture-confirmed pul-
monary TB, which is very similar to the sensitivity in
the same population in our study. However, our data
showed a significant difference of QFT sensitivity
between inpatients and outpatients with culture-con-
firmed pulmonary TB. In general, inpatients with TB
admitted to the ED are expected to have a more severe
form of TB than outpatients with TB. Thus, our data
suggests that the sensitivity of the QFT test may be sig-
nificantly different depending on disease severity in the
study population.
Previous studies have shown that host factors that are
significantly associated with indeterminate QFT results
are immunosuppressive therapies, extremes of age, lym-
phocytopenia, hypoalbuminemia, and HIV-infection
with lower CD4 lymphocyte counts [6,7,9,10,16]. Other
causes of indeterminate QFT results include pre-analyti-
cal errors such as the storage of tubes outside the
recommended temperature range, the over- or under-
filling of tubes with blood, insufficient mixing, and
incomplete washing of the enzyme-linked immunosor-
bent assay plate [13]. However, while recent technical
modifications of the QFT, such as vortexing or immedi-
ate incubation, have reduced the rate of indeterminate
QFT-GIT results [17,18], they are unlikely to be able to
overcome the effect of host factors that lead to low cell-
mediated immune responses. Indeed, the high rate of
indeterminate results observed in our ED setting did not
seem due to errors in the testing process, as the manu-
facturer’s instructions were followed strictly and the rate
of indeterminate QFT results in outpatients with pul-
monary TB (whose samples were handled in an identical
manner to those of inpatients) was very low. Therefore,
we believe that patient-specific factors rather than tech-
nical problems are the main reasons for the high rate of
indeterminate QFT results in our inpatients. Further
analysis revealed that those factors are lymphocytopenia,
hypoalbuminemia, and increased CRP levels. This list
differs somewhat from the list of host factors mentioned
above that were identified by previous studies that were
based on routine hospital use [6,7,10].
The association of lymphocytopenia with indetermi-
nate QFT results is not surprising as it is well known
that lymphocytopenia can decrease the production of
IFN-g. Moreover, as suggested by a previous study [10],
the association of indeterminate QFT results with
hypoalbuminemia may reflect a poor nutritional status
that compromises the immune system. However, our
study is the first to show an association between higher
CRP levels and indeterminate QFT results. Since CRP is
a major positive acute phase reactant [19], higher CRP
levels are likely to reflect more intensive inflammation,
which in turn suggests that patients with indeterminate
QFT results have higher levels of inflammation than
those with determinate QFT results. Notably, since albu-
min is a major negative acute phase reactant [19], a
higher inflammatory status result may explain the asso-
ciation between hypoalbuminemia and poor QFT results
better than the malnutrition hypothesis. Moreover, lym-
phocytopenia is an extremely common feature of the
acute response to stress in acutely ill patients, regardless
of the nature of the underlying illness [20]. Although
this may reflect the small numbers of patients with
immunosuppressive therapies or old age in our study, it
is also possible that these underlying conditions play
less important roles in acute status than in chronic sta-
tus. In addition, since the effects of underlying condi-
tions, which can vary between individuals and during
the clinical course, would be ultimately reflected in lym-
phocyte counts and acute phase reactants, these para-
meters may be good objective markers that indicate the
strength of cellular immunity and the risk of poor QFT
performance.
Hospitalization-related stress is known to promote the
systemic secretion of glucocorticoids and catechola-
mines, which, in turn, influence immune responses [21].
In particular, glucocorticoids are known to suppress the
production of TNF-a,I F N - g, and IL-2 in animals and
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catecholamines inhibit the development of Th1-type
cells, thereby inhibiting IFN-g production [24]. Thus,
the fact that inpatients with pulmonary TB have higher
rates of indeterminate QFT result than outpatients may
partly reflect the derangement of immune responses
caused by hospitalization at the ED.
Lymphocytopenia and hypoalbuminemia were found
to be risk factors of non-positive QFT results in inpati-
ents with active TB. This is consistent with our observa-
tion that clinically significant inflammation associated
with indeterminate QFT results in inpatients in general.
However, acute systemic inflammation did not seem to
be strongly associated with non-positive QFT results in
OPD-based TB patients. Indeed, the outpatients with
non-positive QFT results did not differ significantly
from the other outpatients in terms of lymphocyte
counts and the levels of major acute phase reactants
such as albumin and CRP. However, the outpatients
with non-positive QFT results did have significantly
higher ESR values than the other outpatients. Since CRP
concentrations change rapidly whereas the ESR changes
relatively slowly [19], it may be that the OPD-based TB
patients with non-positive QFT results were at a more
chronic and stable stage of the inflammatory process
(namely, a stage where CRP responses were no longer
being elicited).
Radiographically more severe disease was also signifi-
cantly associated with non-positive QFT results in the
outpatients. This is consistent with the suggestion that
the limited sensitivity of IGRAs in patients with active
TB may relate to the immunological incapacity of the
host to contain mycobacterial replication [25]. More-
over, IFN-g secretion has been shown to correlate inver-
sely with disease severity in patients with TB [25-27].
These observations may explain why outpatients with
non-positive QFT results had extensive disease more
frequently than the other outpatients. In a certain
aspect, radiographically more extensive diseases may be
in line with higher ESR values shown in TB outpatients
with non-positive QFT results.
Taken together, these observations suggest that the
level of immune competence varies among patients with
mycobacterial diseases. The different clinical presenta-
tions of TB appear to be associated with the degree of
alteration of the immune response against the mycobac-
teria. T cell dysfunction by alterations in the expression
of several T cell signal-transduction proteins was
reported in patients with pulmonary TB [28]. In addi-
tion, severe TB in a macaque model induces unbalanced
up-regulation of immune gene networks, causing over-
expression of genes encoding inflammatory cytokines
and chemokines without proportional increases in
antigen-specific cellular responses [29]. Thus, TB inpati-
ents, who are expected to have more severe disease than
OPD-based TB patients, are likely to have more intense
inflammation and more severe T cell dysfunction, per-
haps explaining why more intense inflammation is asso-
ciated with indeterminate result of the QFT test.
The main limitation of the present study is the fact
that the study population was tested by two different
QFTs (QFT-G and QFT-GIT) because the QFT-G was
replaced by the newer generation test QFT-GIT during
the study period. However, a recent meta-analysis that
also included the indeterminate result rates has found
that QFT-G and QFT-GIT may be similarly sensitive
[14]. Thus, this factor is not likely to have significantly
affected our results. Another potential limitation is the
fact that only a small number of patients received
immunosuppressive treatment. Thus, the power of our
study to detect the impact of immunosuppressive ther-
apy on QFT performance was probably rather weak. In
addition, the numbers of inpatients with TB and outpa-
tients after they were subgrouped according to their
QFT results were small. As well, our data could not
directly determine the mechanism by which more
intense inflammation, as evidenced by higher CRP levels
and lower albumin concentrations, is associated with
indeterminate results in the QFT test. These relation-
ships will require further study. Finally, our observations
cannot be generalized to all populations with pulmonary
infiltrates because most of non-TB population were con-
sisted of patients with pneumonia (91%).
Conclusion
Our findings indicate that, unlike QFT of outpatients
with pulmonary TB, QFT performed in the ED for inpa-
tients with pulmonary infiltra t ef r e q u e n t l yr e t u r ni n d e -
terminate results. In addition, our study showed that
inpatients and outpatients with pulmonary TB may dif-
fer in terms of the risk factors that are associated with
non-positive QFT results.
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